FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
AstraZeneca (NASDAQ: AZN) has unveiled plans to invest $50 billion in U.S. manufacturing and R&D infrastructure by 2030, marking one of the largest expansions in the pharmaceutical industry. The move responds to renewed pressure from President Donald Trump’s administration to localize drug production and reduce reliance on imports.
The Anglo-Swedish drugmaker will build a new manufacturing plant in Virginia focused on active ingredients for weight-loss drugs, including a GLP-1 candidate and an oral PCSK9 inhibitor. It also plans to expand operations in Maryland, Massachusetts, California, Indiana, and Texas, enhancing its R&D capabilities and clinical trial supply chain.
CEO Pascal Soriot announced the investment in Washington, citing the need for global pricing reform. “The U.S. cannot shoulder the world’s R&D costs alone,” he said, calling for other nations to pay more for drugs.
Over 40% of AstraZeneca’s 2024 revenue came from the U.S., the world’s largest pharmaceutical market valued at $635 billion. The company aims to hit $80 billion in annual revenue by 2030, with half coming from the U.S.
The $50 billion pledge follows Trump’s threats of pharmaceutical tariffs, with a possible grace period of 12–18 months. U.S. Commerce Secretary Howard Lutnick emphasized the administration’s goal to end foreign dependency in the drug supply chain.
The investment is in addition to a $3.5 billion commitment made in November 2024. It mirrors a similar $50 billion pledge by Roche and aligns with major expansion plans from Eli Lilly, Johnson & Johnson, Novartis, and Sanofi.
AstraZeneca employs about 18,000 people in the U.S. and hinted at creating tens of thousands of new jobs, though exact figures were not disclosed. The company declined to comment on rumors of a potential U.S. stock market listing shift.
